Summit Therapeutics Income from Continuous Operations 2015-2025 | SMMT

Summit Therapeutics income from continuous operations for the twelve months ending March 31, 2025 was $-0.241B, a 107.5% increase year-over-year.

  • Summit Therapeutics annual income from continuous operations for 2024 was $-0.221B, a 64.01% decline from 2023.
  • Summit Therapeutics annual income from continuous operations for 2023 was $-0.615B, a 680.54% increase from 2022.
  • Summit Therapeutics annual income from continuous operations for 2022 was $-0.079B, a 11.08% decline from 2021.

Summit Therapeutics Income from Continuous Operations 2015-2025 | SMMT

  • Summit Therapeutics annual income from continuous operations for 2024 was $-0.221B, a 64.01% decline from 2023.
  • Summit Therapeutics annual income from continuous operations for 2023 was $-0.615B, a 680.54% increase from 2022.
  • Summit Therapeutics annual income from continuous operations for 2022 was $-0.079B, a 11.08% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.7B
Zoetis (ZTS)$66.3B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$43.3B
BeOne Medicines - (ONC)$32.9B
Sandoz Group AG (SDZNY)$25.9B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.3B
Neurocrine Biosciences (NBIX)$13.5B
United Therapeutics (UTHR)$12.7B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.6B
Grifols, S.A (GRFS)$7.5B
Corcept Therapeutics (CORT)$7.4B
Ionis Pharmaceuticals (IONS)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B